Loading…
for educational and safety purposes
MiPLA and 1cP-MiPLA both come up in the same conversations; they overlap on Serotonin. MiPLA: MiPLA (N-methyl-N-isopropyl lysergamide) is a close structural analog of LSD in which one of the two amide N-ethyl groups is replaced by a methyl and an isopropyl substituent. 1cP-MiPLA: 1cP-MiPLA is a doubly modified lysergamide combining a cyclopropanecarbonyl group on the indole nitrogen with the N-methyl-N-isopropyl amide substitution that defines MiPLA (lysergic acid methylisopropylamide).
MiPLA (N-methyl-N-isopropyl lysergamide) is a close structural analog of LSD in which one of the two amide N-ethyl groups is replaced by a methyl and an isopropyl substituent. Like other lysergamide psychedelics, its effects are attributed principally to partial agonism at the 5-HT2A serotonin receptor. In the mouse head-twitch response assay, a validated behavioral proxy for 5-HT2A activation, MiPLA produced a median effective dose of approximately 422 nmol/kg, indicating potency somewhat below that of LSD while remaining within the range of active lysergamides. It has appeared on the recreational blotter market as an uncontrolled LSD substitute, prompting analytical work to distinguish it from LSD and the isomeric LAMPA; reported experiences describe a comparatively shorter and milder classical psychedelic state.
1cP-MiPLA is a doubly modified lysergamide combining a cyclopropanecarbonyl group on the indole nitrogen with the N-methyl-N-isopropyl amide substitution that defines MiPLA (lysergic acid methylisopropylamide). It was first formally identified in seized blotter products, and analytical stability studies show that it undergoes N-deacylation to MiPLA, supporting a prodrug relationship analogous to that between 1cP-LSD and LSD, although this deacylation is less pronounced than in the diethylamide series. MiPLA is an LSD-like 5-HT2A receptor agonist generally reported as somewhat milder and more manageable than LSD, so 1cP-MiPLA is expected to yield a comparatively gentle psychedelic profile. Its receptor pharmacology has not been directly measured, and the existing literature is predominantly forensic and analytical.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
partial agonist
agonist (via MiPLA)
agonist
agonist
agonist
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.